 |
|
Antioxidant Supplementation and Cancer Prevention—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In Reply: I agree with the comments from Drs Bosland and McCormick regarding the importance of null results from preclinical animal models and support their suggestion for reducing publication bias by increasing journal space devoted to well-conducted null studies.
Dr Pinsky is correct that the exclusion from SELECT of men with a prior diagnosis of prostate cancer would decrease the expected number of prostate cancer deaths based on general population rates. His estimate of the mortality deficit in SELECT compared with the SEER population is undoubtedly closer to the truth than the back-of-the-envelope calculation in my Editorial. My goal was to draw attention to the extremely low rates of advanced disease and mortality in SELECT compared with the rates one would expect in a similar population with far less PSA screening. In that regard, the most appropriate direct comparison might be the PLCO trial participants with normal baseline PSA and . . . [Full Text of this Article]
Peter H. Gann, MD, ScD
pgann@uic.edu
Department of Pathology
University of Illinois at Chicago
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTERS
Antioxidant Supplementation and Cancer Prevention
Maarten C. Bosland and David L. McCormick
JAMA. 2009;301(18):1877-1878.
EXTRACT
| FULL TEXT
Antioxidant Supplementation and Cancer Prevention
Paul F. Pinsky
JAMA. 2009;301(18):1878.
EXTRACT
| FULL TEXT
|
